[EN] THE HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR [FR] SEL HÉMI-FUMARATE D'UN DÉRIVÉ DE 1,3,4-THIADIAZOLYLE COMME MODULATEUR DU RÉCEPTEUR DE LA SPHINGOSINE 1-PHOSPHATE
Development of a Fully Telescoped Synthesis of the S1P1 Agonist GSK1842799
摘要:
The development of a fully telescoped synthesis of the potent and selective S1P1 agonist GSK1842799 is described. Key features in the synthesis, which has been implemented on a multikilogram scale, include a nucleophilic aromatic substitution to install a lipophilic 1-octyloxy chain, introduction of a chiral quaternary centre, and the use of Lawesson's reagent to form a thiadiazole ring. Due to the lack of crystalline intermediates, workup protocols that took advantage of the lipophilic nature of the compounds were developed. This allowed full combination of the five chemistry stages and a salt formation, with the only isolation being that of the final hemifumarate salt of the drug substance. The synthesis of the O-phosphorylated active metabolite is also described.
HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR
申请人:Anson Michael Simon
公开号:US20110034524A1
公开(公告)日:2011-02-10
The invention relates to the compound (2S)-2-amino-2-5-[4-(octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate, processes for its preparation, pharmaceutical compositions containing them and its use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
[EN] THE HEMI-FUMARATE SALT OF A 1,3,4-THIADIAZOLYL DERIVATIVE AS MODULATOR OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR<br/>[FR] SEL HÉMI-FUMARATE D'UN DÉRIVÉ DE 1,3,4-THIADIAZOLYLE COMME MODULATEUR DU RÉCEPTEUR DE LA SPHINGOSINE 1-PHOSPHATE
申请人:GLAXO GROUP LTD
公开号:WO2009098193A1
公开(公告)日:2009-08-13
The invention relates to the compound (2S)-2-amino-2-5-[4-(octyloxy)-3- (trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate, processes for its preparation, pharmaceutical compositions containing them and its use in the treatment of conditions or disorders which are mediated via the S1 P1 receptor.
Development of a Fully Telescoped Synthesis of the S1P1 Agonist GSK1842799
作者:Michael S. Anson、Jonathan P. Graham、Alastair J. Roberts
DOI:10.1021/op2000095
日期:2011.5.20
The development of a fully telescoped synthesis of the potent and selective S1P1 agonist GSK1842799 is described. Key features in the synthesis, which has been implemented on a multikilogram scale, include a nucleophilic aromatic substitution to install a lipophilic 1-octyloxy chain, introduction of a chiral quaternary centre, and the use of Lawesson's reagent to form a thiadiazole ring. Due to the lack of crystalline intermediates, workup protocols that took advantage of the lipophilic nature of the compounds were developed. This allowed full combination of the five chemistry stages and a salt formation, with the only isolation being that of the final hemifumarate salt of the drug substance. The synthesis of the O-phosphorylated active metabolite is also described.